Study population:

Primary prevention of CVD

Individuals without history of occlusive disease

Comments:

Age range in trials was 19-94 years

Patients had hypertension or coronary risk factors without overt disease.

Outcome Duration NNT Annualised NNT

Serious vascular event. (Defined as MI, stroke or vascular death).

Mean 5.8 years

 246

1428

References

ATT Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849-60.